HOME > Business Wire > Article
Daiichi Sankyo Appoints Hiroyuki Okuzawa as Chief Executive Officer
TOKYO--( BUSINESS WIRE )-- Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO), effective April 1, 2025.
Dr. Manabe will transition from his current role of Representative Director, Executive Chairperson and CEO to Representative Director and Executive Chairperson while Mr. Okuzawa will transition to Representative Director, President and CEO.
Under Dr. Manabe’s leadership, Daiichi Sankyo’s pioneering science and technology led to the resurgence of antibody drug conjugate (ADC) development within the pharmaceutical industry, leading to three of the largest licensing deals in history along with the approvals of ENHERTU® and DATROWAY®, two precision cancer medicines invented with Daiichi Sankyo’s DXd ADC Technology that are changing the way that metastatic breast cancer is treated.
Daiichi Sankyo’s five-year business plan (FY2021-2025) is progressing successfully with the rapid and global expansion of its oncology business. In order to ensure the solid achievement of FY2025 goals and to strengthen its management structure, Daiichi Sankyo’s Board of Directors appointed Mr. Okuzawa as the new CEO at the board meeting on January 31, 2025, based on the Nomination Committee’s report. This transition in April 2025 will occur as Daiichi Sankyo enters the final year of its current five-year business plan and it starts full scale preparation for the next five-year business plan (FY2026-2030).
Mr. Okuzawa joined Daiichi Sankyo in 1986 and has served as Representative Director, President and Chief Operating Officer (COO) since 2023. He also held the role of Chief Financial Officer (CFO) for two years and other senior leadership roles in international business, corporate strategy and human resources during his tenure at Daiichi Sankyo. Mr. Okuzawa graduated from Hitotsubashi University in Tokyo with a degree in Social Sciences. Mr. Okuzawa has 50,741 shares of the company as of September 30, 2024.
“Hiroyuki Okuzawa has played a pivotal role in advancing our current five-year business plan, driving unprecedented global growth for our company,” said Sunao Manabe. “Beyond his extensive experience as an international business leader and impressive accomplishments while serving as both COO and CFO at Daiichi Sankyo, Hiroyuki has been a key figure in transforming our corporate culture by exemplifying our core behaviors of inclusivity and diversity, collaboration and trust, and continuous development and growth. As the new CEO, I am confident that Hiroyuki will continue to provide strong leadership, propelling Daiichi Sankyo to the forefront of the global pharmaceutical industry by enhancing patient care worldwide through creating new medicines with our expertise in science and technology.”
“I am deeply honored to be the next CEO of Daiichi Sankyo and will follow Sunao Manabe’s exceptional leadership and unwavering commitment to patients and their families,” said Hiroyuki Okuzawa. “Building on this foundation, I will continue to leverage Daiichi Sankyo’s strengths in science and technology, and will continuously develop our talent globally. Under my leadership, we will create a 2035 vision and a next five-year business plan (FY2026-2030), continuing to enrich the quality of life worldwide.”
About Daiichi Sankyo
Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular and other diseases with high unmet medical need. For more information, please visit
www.daiichisankyo.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250130225103/en/
Contacts
Media Contacts:
Daiichi Sankyo Co., Ltd.
DS-PR_jp@daiichisankyo.com
Investor Relations Contact:
DaiichiSankyoIR_jp@daiichisankyo.com
Source: Daiichi Sankyo Company, Ltd
Business Wire
- 01/31 14:03 Suntory Spirits Becomes Founding Partner for IG Arena
- 01/31 13:00 Datopotamab Deruxtecan Recommended for Approval in the EU by CHMP for ...
- 01/31 08:06 Kirin Holdings: Improving The Sustainability Of Black Tea Farms In Sri...
- 01/31 08:00 Meiji Seika Pharma Receives Approval for Adding Domestic Manufacturing...
- 01/31 06:30 Poxel’s partner Sumitomo Pharma reports TWYMEEG® gross sales in Jap...
- 01/31 06:26 Kirin Holdings: Conducting Human Rights Due Diligence For Sustainable ...
- 01/31 04:05 Daiichi Sankyo Appoints Hiroyuki Okuzawa as Chief Executive Officer
- 01/31 04:00 TROPION-Lung12 Phase 3 Trial Initiated Evaluating DATROWAY® as Part o...
- 01/30 07:04 Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026
- 01/30 06:35 Takeda Delivers Strong Third-Quarter FY2024 Results; Raises Full Year ...
- 01/30 02:10 Mitsubishi Electric Joins Horizon Europe’s “FLAGCHIP” Project to...
- 01/30 02:10 Mitsubishi Electric India to Acquire Stake in Gervigreind Data Science...
- 01/29 16:00 MOPOP Presents: Asian Comics: Evolution of an Art Form Opening March 8...
- 01/29 14:00 Nakagawa Juken Co., Ltd.: Turning Japan’s Historic “Kominka” int...
- 01/29 11:45 Compute Exchange Launches to Transform How AI Compute is Bought and Sold
- 01/29 02:07 New Leadership at Sony Interactive Entertainment
- 01/28 17:00 OKI Achieves 3D Integration of Thin-Film Analog ICs Using CFB Technolo...
- 01/28 17:00 Cyber Security Cloud Enhances CloudFastener’s Compliance Capabilitie...
- 01/28 16:17 VicOne and Trend Micro Stage Pwn2Own Automotive Zero Day Vulnerability...
- 01/28 16:00 Japan selects Beechcraft T-6 Texan II Integrated Training System to mo...
- 01/28 15:32 JCR Pharmaceuticals to Present at the 21st Annual WORLDSymposium™ 2025
- 01/28 15:00 Global Communications Platform Infobip partners with NTT Com Online to...
- 01/28 14:30 SkyDrive Enters Into a Business Partnership With JetSetGo to Develop C...
- 01/28 04:19 Oasis Initiates Shareholder Derivative Lawsuit Against Kobayashi Pharm...
- 01/28 03:18 KIOXIA AiSAQ™ Technology Designed to Reduce DRAM Requirements in Gen...
- 01/27 23:00 EdgeCortix SAKURA-I AI Accelerator Demonstrates Robust Radiation Resil...
- 01/27 23:00 ENHERTU® Approved in the U.S. as First HER2 Directed Therapy for Pati...
- 01/27 17:00 OKI Develops ‘Ship Classification AI System Technology’ to Classif...
- 01/27 14:00 2025 Japan Prize: Two Scientists from USA and Spain Have Been Awarded
- 01/27 14:00 Kuwana, a Japanese City Which Has Been Drawing Increased Attention Fro...